It is believed that such a therapeutic approach could have a significant effect on a broader range of diseases associated with FLG gene mutation carriers, persons with FLG deficiency caused by inflammation, or in persons with genetic or inflammatory enzyme variants that allow the conversion of profilaggrin into FLG. The gene discussed is FLG; the disease is hyperinsulinemic hypoglycemia, familial, 4.